Jiaqiang Cai, PhD, currently serves as Chief Scientific Officer and on the Board of Directors.
Prior to MediLink, Dr. Cai has more than 30 years of industry drug discovery and development experience. Over the course of his career, he has led 100+ new drug development projects, sequentially brought 30 projects into different clinical stages. He has authored or co-authored more than 40 articles in leading peer-reviewed journals and is an inventor or co-inventor on more than 150 patents.
During the past decade, he has served as the deputy general managers of Shanghai Hansoh Pharma and Sichuan Kelun Pharmaceutical Research Institute, with responsibilities for both companies' investigational small molecule compounds. He began his career at MSD UK Discovery Centre, where he spent 14 years serving in positions of scientist and project leader for small molecule drug discovery, as well as translational research programs.
He holds a Ph.D. from Dalian Institute of Chemical Physics and received Postdoctoral training from University College London.